SCHEMBL4126088

SCHEMBL4126088

COc1cc(Sc2cc(C=O)nn2-c2ccccc2Cl)ccn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
MAPK11 Q15759 2/20 0.35
MAPK14 Q16539 2/20 0.35
TYMS P04818 1/20 0.33
SCN9A Q15858 1/20 0.32
CTSA P10619 1/20 0.32
BRAF P15056 1/20 0.32
NR3C2 P08235 1/20 0.31
FLT3 P36888 1/20 0.31
GRM5 P41594 2/20 0.31
GRM1 Q13255 1/20 0.31
SLC16A3 O15427 1/20 0.31
SLC16A1 P53985 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3698070 0.86 MAPK14 (0.34) ALDH1A1MAPK11MAPK14NR3C2PDE4B
SCHEMBL3693373 0.82 MAPK11 (0.34) ALDH1A1MAPK11MAPK14NR3C2PDE4B
SCHEMBL2841090 0.80 NFE2L2 (0.35) MAPK11MAPK14BRAFFLT3SLC16A3
SCHEMBL3695878 0.79 PDE4B (0.46) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL4132130 0.77 SLC16A3 (0.38) ALDH1A1SCN9ACTSASLC16A3SLC16A1
SCHEMBL4132125 0.77 SLC16A3 (0.40) ALDH1A1CTSASLC16A3SLC16A1PDE4B
SCHEMBL3697515 0.77 MAPT (0.36) ALDH1A1MAPK11MAPK14GRM5CNR1
SCHEMBL3698799 0.77 SLC16A3 (0.40) ALDH1A1SCN9ACTSABRAFNR3C2
SCHEMBL2836643 0.75 MAPK14 (0.36) MAPK11MAPK14PDE4BRIPK1SMN1; SMN2
SCHEMBL3700575 0.74 SLC16A3 (0.40) ALDH1A1CTSABRAFSLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 ALDH1A1 1497/4885TNKS 4735/4885TNKS2 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.